A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Carac Overdose, Contraindications and Information - Fluorouracil
Carac Overdose, Contraindications and Information - Fluorouracil
OVERDOSE
Ordinarily, topical overdosage will
not cause acute problems. If Carac is accidentally ingested, induce emesis
and gastric lavage. Administer symptomatic and supportive care as needed.
If contact is made with the eye, flush with copious amounts of water.
CONTRAINDICATIONS
Fluorouracil may cause fetal harm when administered to a pregnant
woman. Fluorouracil is contraindicated in women who are or may become pregnant.
If this drug is used during pregnancy, or if the patient becomes pregnant while
taking this drug, the patient should be apprised of the potential hazard to
the fetus.
No adequate and well-controlled studies have been conducted
in pregnant women with either topical or parenteral forms of fluorouracil. One
birth defect (ventricular septal defect) and cases of miscarriage have been
reported when fluorouracil was applied to mucous membrane areas. Multiple birth
defects have been reported in the fetus of a patient treated with intravenous
fluorouracil.
Animal reproduction studies have not been conducted with Carac.
Fluorouracil, the active ingredient, has been shown to be teratogenic in mice,
rats, and hamsters when administered parenterally at doses greater than or equal
to 10, 15 and 33 mg/kg/day, respectively, [4X, 11X and 20X, respectively, the
Maximum Recommended Human Dose (MRHD) based on body surface area (BSA)]. Fluorouracil
was administered during the period of organogenesis for each species. Embryolethal
effects occurred in monkeys at parenteral doses greater than 40 mg/kg/day (65X
the MRHD based on BSA) administered during the period of organogenesis.
Carac should not be used in patients with dihydropyrimidine
dehydrogenase (DPD) enzyme deficiency. A large percentage of fluorouracil is
catabolized by the enzyme dihydropyrimidine dehydrogenase (DPD). DPD enzyme
deficiency can result in shunting of fluorouracil to the anabolic pathway, leading
to cytotoxic activity and potential toxicities.
Carac is contraindicated in patients with known hypersensitivity
to any of its components.
top
